A: Dana-Farber is collaborating with Deerfield, an investment management firm committed to advancing healthcare, to accelerate the translation of research within Dana-Farber faculty laboratories into clinical therapeutics for cancer. Riverway Discoveries is a Deerfield company that will support Dana Farber’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Riverway will fund projects with the aim of discovering novel therapeutics to improve the lives of cancer patients.

Through Riverway Discoveries, Deerfield has committed up to $130 million over the next ten years to support promising translational research from Dana-Farber. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Riverway projects that show commercial potential.

A: Principal Investigators whose principal employer is Dana-Farber Cancer Institute or who have a faculty appointment at Dana-Farber Cancer Institute and are therefore subject to Dana-Farber’s institutional policies are eligible to apply.

A: Applicants are encouraged to contact Irena Ivanovska (Irena_Ivanovska@DFCI.HARVARD.EDU) for more information on proposal submission to Riverway Discoveries.

A: No – We welcome applications from all therapeutic areas.

A: Eligible projects must be free from any Intellectual Property (IP) obligations to other industry partners that may restrict the licensing and practice of the IP (by virtue of industry sponsored research agreements, material transfer agreements, or other contractual or intellectual property entanglements). If you have any questions about whether or not such obligations exist with your project, you should consult Irena Ivanovska in the innovation Office at Irena_Ivanovska@DFCI.HARVARD.EDU.